Biosimilars | search
Click here to view Biosimilars news from 60+ newspapers.
Bookmark or Share- Biosimilars Market Size is Projected to Reach USD 121.88 - GlobeNewswireThe global biosimilars market size was valued at USD 28.70 billion in 2024 and is projected to reach from USD 33.16 billion in 2025 to USD 121.88 billion by 2033, growing at a CAGR of 15.56% ...
- Biosimilars Market Size is Projected to Reach USD 121.88 Billion by ...The global biosimilars market size was valued at USD 28.70 billion in 2024 and is projected to reach from USD 33.16 billion in 2025 to USD 121.88 billion by 2033, growing at a CAGR of 15.56% ...
- Ustekinumab biosimilars Yesintek, Steqeyma, and Otulfi approved by FDA ...In late 2024 and early 2025, multiple ustekinumab biosimilars, including Yesintek, Steqeyma, and Otulfi, which are biosimilars referencing Janssen/Johnson & Johnson’s (J&J) Stelara, received regulatory approvals in the US, Europe, Canada, and the UK, expanding treatment options for Crohn’s disease, psoriasis related conditions, and ulcerative colitis.
- J&J stands by sales growth ambitions—and points to potential Tremfya ...As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the
- What biosimilars have been approved in the United States? - Drugs.comThere are currently 64 biosimilars approved by the U.S. Food and Drug Administration (FDA). The most recent biosimilar approval was Steqeyma (ustekinumab-stba) on December 17, 2024. What is a Biosimilar?
More
